Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic Dermatitis
Mark Boguniewicz, Lisa A Beck, Lawrence Sher, Emma Guttman-Yassky, Diamant Thaçi, Andrew Blauvelt, Margitta Worm, Jonathan Corren, Weily Soong, Peter Lio, Ana B Rossi, Yufang Lu, Jingdong Chao, Laurent Eckert, Abhijit Gadkari, Thomas Hultsch, Marcella Ruddy, Leda P Mannent, Neil M H Graham, Gianluca Pirozzi, Zhen Chen, Marius Ardeleanu, Mark Boguniewicz, Lisa A Beck, Lawrence Sher, Emma Guttman-Yassky, Diamant Thaçi, Andrew Blauvelt, Margitta Worm, Jonathan Corren, Weily Soong, Peter Lio, Ana B Rossi, Yufang Lu, Jingdong Chao, Laurent Eckert, Abhijit Gadkari, Thomas Hultsch, Marcella Ruddy, Leda P Mannent, Neil M H Graham, Gianluca Pirozzi, Zhen Chen, Marius Ardeleanu
Abstract
Background: Dupilumab has demonstrated efficacy with acceptable safety in clinical trials in patients with moderate to severe atopic dermatitis (AD).
Objective: To assess dupilumab's impact on asthma and sinonasal conditions in adult patients with moderate to severe AD in four randomized, double-blinded, placebo-controlled trials.
Methods: In LIBERTY AD SOLO 1 (NCT02277743), SOLO 2 (NCT02755649), CHRONOS (NCT02260986), and CAFÉ (NCT02755649), patients received placebo, dupilumab 300 mg every 2 weeks (q2w), or dupilumab 300 mg weekly (qw). In CHRONOS and CAFÉ, patients received concomitant topical corticosteroids. This post hoc analysis assessed Asthma Control Questionnaire-5 (ACQ-5) scores in patients with asthma, Sino-Nasal Outcome Test-22 (SNOT-22) scores in patients with sinonasal conditions, and AD signs and symptoms in all patients.
Results: Of the 2444 patients, 463 had asthma with baseline ACQ-5 ≥ 0.5 (19%); 1171 had sinonasal conditions (48%); and 311 had both (13%). At week 16, ACQ-5 scores (least squares mean change from baseline [standard error]) improved by 0.27 (0.07), 0.59 (0.08), and 0.56 (0.07) in placebo-, q2w-, and qw-treated patients with asthma, respectively, whereas SNOT-22 scores improved by 5.1 (0.8), 9.9 (0.9), and 10.8 (0.8) in patients with sinonasal conditions (P < .01 for all dupilumab vs placebo). Improvements in ACQ-5 and SNOT-22 were also seen in patients with both conditions. Dupilumab also significantly improved AD signs and symptoms among all subgroups.
Conclusions: In this first analysis of patients with comorbid moderate to severe AD, asthma, and/or chronic sinonasal conditions, dupilumab improved all three diseases in a clinically meaningful and statistically significant manner (vs placebo), based on validated outcome measures.
Trial registration: ClinicalTrials.gov NCT02277743 NCT02755649 NCT02260986 NCT02277769.
Keywords: ACQ-5; Allergic rhinitis; Asthma; Atopic dermatitis; Dupilumab; Eczema; Rhinosinusitis; SNOT-22; Type 2 inflammation; Type 2 inflammatory diseases.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
Source: PubMed